Comparative Pharmacology
Head-to-head clinical analysis: AMINOSOL 5 versus AMINOSYN HF 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSOL 5 versus AMINOSYN HF 8.
AMINOSOL 5% vs AMINOSYN-HF 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.
Aminosyn-HF 8% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue repair in patients unable to tolerate oral intake.
Intravenous infusion: 500 mL to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.
1-2 g/kg/day intravenously as total parenteral nutrition, typically administered as a continuous infusion over 24 hours.
None Documented
None Documented
The half-life of infused amino acids is not defined as they are endogenous compounds. However, the nitrogen from amino acids has a biological half-life of approximately 6-18 hours, depending on metabolic activity. As part of total parenteral nutrition, the elimination half-life of infused amino acids is influenced by protein turnover and catabolism.
Not applicable as amino acids are rapidly cleared; terminal half-life of infused amino acids is approximately 10-30 minutes.
Excretion of infused amino acids is primarily renal, with small amounts lost via feces and skin. Approximately 85-95% of the nitrogen load is excreted in urine as urea, ammonia, and other nitrogenous wastes. Less than 5% is eliminated in feces.
Renal: >90% as amino acids and metabolites; fecal: <5%.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution